Tibotec recognizes the unparalleled global challenge posed by the AIDS epidemic and our responsibility to collaborate in the international response to HIV. Collaborative partnerships and innovation are the hallmark of Tibotec's social and scientific commitment to discovering new solutions to HIV/AIDS and other infectious diseases in the developing world.

ARV Global Access Progam Tibotec has developed a Global Access Program to facilitate access to its antiretrovirals (ARVs) for patients living with HIV/AIDS in developing countries. The Global Access Program includes access pricing, registration, medical education for appropriate use and voluntary licensing. Read more TB Alliance Collaboration In 2009, Tibotec announced a landmark collaboration with the Global Alliance for TB Drug Development (TB Alliance) to accelerate the discovery and development of new drugs to fight tuberculosis (TB). By sharing expertise and resources in the development of TMC207, the collaboration could potentially lead to the availability of the first TB drug with a new mechanism of action in 40 years. Read more TMC120 Microbicide Collaboration In March 2004, Tibotec granted a royalty-free license for its antiretroviral TMC120 to the International Partnership for Microbicides (IPM) to develop, manufacture and distribute the compound as a microbicide in resource-poor countries. This agreement marked the first collaboration in the microbicide field. Read more Sikiliza Leo Project Sikiliza Leo, which means 'Listening to tomorrow', is a Non-Government Organization (NGO) whose goal is to contribute towards the development of the capacities of Rural Communities to protect and improve their own health. Read more micMAT: Innovation in Development, Design and Delivery The development of micMAT and its distribution to those most in need demonstrates the Company's dedication to innovation and highlights our commitment to access to medicines. Read more Reach Initiative This initiative focused on supporting collaborative projects between organizations in the developed and developing world by providing financial support for HIV/AIDS research projects in resource-poor countries. Read more Global Health Science MSC Sponsorship Tibotec and Johnson & Johnson are sponsoring six students from developing countries for the 2009/ 2010 Global Health MSc course at Oxford University. Read more Tuberculosis Research This initiative will focus on Research and Discovery of new compounds for the treatment of tuberculosis. Read more

Please e mail us at tibbe-info@its.jnj.com to share your thoughts on Tibotec's response to the global HIV/AIDS pandemic.